SAC Capital Advisors’s AbbVie ABBV Stock Holding History

SAC Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-519,107	Closed	-$26.7M	–	7
2014 Q1	$26.7M	Sell	519,107 -569,149	-52%	-$28.8M	0.14%	205
2013 Q4	$57.5M	Buy	1,088,256 +910,057	+511%	+$44.7M	0.33%	72
2013 Q3	$7.97M	Sell	178,199 -333,672	-65%	-$14.8M	0.04%	434
2013 Q2	$21.2M	Buy	+511,871	New	+$22.4M	0.12%	230

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

SAC Capital Advisors's ABBV Position: Q2 2014 in Review

SAC Capital Advisors sold out of AbbVie (ABBV) in Q2 2014, closing a stake of 519,107 shares — an estimated $26.7M sold.

SAC Capital Advisors first reported a position in ABBV in Q2 2013 and held it in 4 quarters. The position peaked at $57.5M in Q4 2013. 1,457 funds tracked by Wall St. Rank hold ABBV as of Q2 2014.

SAC Capital Advisors reported no remaining AbbVie position as of Q2 2014 after selling out during the quarter.
SAC Capital Advisors sold 519,107 AbbVie shares in Q2 2014, an estimated $26.7M.
SAC Capital Advisors first reported a position in AbbVie in Q2 2013 and held it in 4 quarters.
SAC Capital Advisors's AbbVie position peaked at $57.5M in Q4 2013.
1,457 funds tracked by Wall St. Rank held AbbVie as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.